SCHEMBL2858951

SCHEMBL2858951

CC(=O)c1nc(C(F)(F)F)n2c1CNCC2

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.32
▸ HTR2C P28335 2/20 0.32
▸ MGLL Q99685 1/20 0.31
▸ DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14955967 0.87 HTR2A (0.33) HTR2AHTR2C
SCHEMBL10025712 0.86 SCN9A (0.33) HTR2AHTR2CDPP4
SCHEMBL10025740 0.85 MGLL (0.31) HTR2AHTR2CMGLL
SCHEMBL10025682 0.85 CFTR (0.33) HTR2AHTR2CMGLLDPP4
SCHEMBL10025558 0.85 DPP4 (0.43) HTR2AHTR2CMGLLDPP4
Hydrochloric Acid SCHEMBL14955894 0.84 MGLL (0.31) HTR2AHTR2CMGLL
SCHEMBL14956096 0.82 MLYCD (0.35) MGLL
SCHEMBL10025673 0.82 OPRD1 (0.33) MGLLDPP4
SCHEMBL31699802 0.82 ALDH1A1 (0.43) DPP4
SCHEMBL2853306 0.80 GSK3B (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2230241-B1 TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2014-11-26 — — EP disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 — — US disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 — — US disclosed
US-8513411-B2 Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2013-08-20 — — US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 — — US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 — — US disclosed
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-08-30 — — US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 — — US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 — — US disclosed
US-8207161-B2 Tetrahydro-imidazo[1,5-α]pyrazine derivatives, preparation process and medicinal use thereof JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2012-06-26 — — US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 — — US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 — — US disclosed
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2010-10-28 — — US disclosed
EP-2230241-A1 TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2010-09-22 — — EP disclosed
EP-2230241-A1 TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2010-09-22 — — EP disclosed
CN-101641361-A Tetrahydroimidazo [1, 5-a ] pyrazine derivative, preparation method and application thereof in medicine SHANGHAI HENGRUI PHARM CO LTD 2010-02-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220766-A1 TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF DPP4, DPP3, DPP7 HTR2A 764/4885HTR2C 577/4885MGLL 1992/4885
US-20100273786-A1 TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 HTR2A 1179/4885HTR2C 892/4885MGLL 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback